Logotype for PExA

PExA (PEXA) investor relations material

PExA Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for PExA
Q3 2025 earnings summary7 Nov, 2025

Executive summary

  • Transitioning from a research instrument provider to a diagnostics-focused company, emphasizing early lung cancer detection and diagnostics, with a strategic focus on long-term value creation and technology development.

  • Instrument enables unique sampling from small airways, supporting biomarker discovery, pharmacogenetics, and diagnostics.

  • Revenue for Q3 2025 was 44,489 SEK, up from 31,503 SEK year-over-year; nine-month revenue reached 357,069 SEK, up from 251,201 SEK.

  • Fully guaranteed rights issue raised SEK 9.9 million, with most guarantors opting for shares, reflecting long-term confidence and securing funding for strategic development.

  • Expansion of customer base and collaborations, including first instrument placement and data-sharing agreement in Australia, and a pilot study at Danderyd Hospital.

Financial highlights

  • SEK 9.9 million raised in a fully guaranteed rights issue, improving liquidity and supporting development.

  • Q3 net sales increased 41% year-over-year; nine-month sales up 42%.

  • Q3 net loss was -2,574,777 SEK; nine-month net loss was -7,138,751 SEK, slightly improved from prior year.

  • Cash and cash equivalents at period end were 8.06 MSEK; equity ratio at period end was 82.5%.

  • Operating cash flow for Q3 was 6.37 MSEK; nine-month operating cash flow was 2.46 MSEK.

Outlook and guidance

  • Strategic focus on becoming a lung cancer diagnostics company, with ongoing validation and regulatory pathway development for CE-marking.

  • Funding from the rights issue enables continued development in three strategic focus areas.

  • Expectation of further updates on strategic direction and regulatory progress in the coming months.

  • Long-term goal is to enable earlier detection of lung diseases and expand into broader diagnostic markets.

  • Continued expansion in biomarker discovery, pharmacogenetics, and pharmacodynamics, with increasing interest from the pharmaceutical industry.

Commercialization path for lung cancer biomarker?
Is 9.9 MSEK sufficient for strategic goals?
How does PEXA compare to invasive methods?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next PExA earnings date

Logotype for PExA
Q4 202519 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next PExA earnings date

Logotype for PExA
Q4 202519 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

PExA AB is a Sweden-based biotechnology company focused on developing innovative solutions for respiratory research. The company specializes in equipment and methods for non-invasive sampling of biomarkers from the small airways, enabling advancements in the understanding and diagnosis of respiratory diseases. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Spotlight Stock Market.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage